Year: 2025
Type: review
Abstract: Gastric cancer (GC) remains a significant global health burden, driven by a complex interplay of genetic, environmental, and microbial factors. Emerging evidence highlights the critical role of gut microbiota in gastric carcinogenesis, as microbial dysbiosis disrupts gastrointestinal homeostasis, fuels chronic inflammation, and promotes immunomodulation and metabolic reprogramming. Helicobacter pylori, a key microbial player, initiates tumorigenic pathways through reactive oxygen species production and the manipulation of dietary and microbial metabolites, leading to epigenetic and genetic alterations. Targeting gut microbiota has emerged as a promising therapeutic strategy, with interventions such as probiotics, prebiotics, dietary modifications, antibiotics, and fecal microbiota transplantation (FMT) showing potential in restoring microbial balance and attenuating tumor progression. Furthermore, advances in microbiota research have identified microbial biomarkers as valuable tools for early diagnosis, prognosis, and personalized treatment of GC. This review evaluates therapeutic strategies for microbiota modulation, assesses its diagnostic and prognostic potential, and highlights current gaps in the field. It also advocates for the integration of microbiota-targeted therapies into clinical practice, emphasizing their transformative potential in the prevention and management of GC. By addressing these aspects, this review aims to provide a comprehensive understanding of the role of gut microbiota in GC and to guide future research and clinical applications.
Source: Frontiers in Microbiology
Authors: Shuang Huo, Kaiying Lv, Lutuo Han, Yu Zhao, Jiakang Jiang
Language: English
Topic: Gut microbiota and health
Subfield: Molecular Biology
Domain: Life Sciences
Keywords: gastric cancer, gut microbiota, Helicobacter pylori, dysbiosis, gastric carcinogenesis, chronic inflammation, immunomodulation, metabolic reprogramming, reactive oxygen species, epigenetic modifications, probiotics, prebiotics, fecal microbiota transplantation, antibiotics, microbial biomarkers, early diagnosis, prognosis, precision medicine, microbiota-targeted therapy
Open Access status: gold
Estimated APC paid: $3,801
OpenAlex ID: W4412759339
